Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSEARCA:AZTD NYSEARCA:FVL NASDAQ:NITE NYSEARCA:WMW On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAZTDAztlan Global Stock Selection DM SMID ETF$26.95-0.3%$26.37$20.12▼$27.30$30.32M1.031,427 shs1 shsFVLFirst Trust Value Line 100 Exchange-Traded Fund$23.160.0%$23.16$15.00▼$23.82$36.82MN/A29,114 shs7,400 shsNITENightstar Therapeutics$31.87+0.4%$25.41$9.59▼$29.55$1.07B2.84185,808 shs1,814 shsWMWELEMENTS Linked to the Morningstar Wide Moat Focus Total Return Index$0.00$28.08▼$39.22$18.99MN/A3,163 shs20,900 shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAZTDAztlan Global Stock Selection DM SMID ETF+0.75%-0.73%+4.08%+17.22%+20.40%FVLFirst Trust Value Line 100 Exchange-Traded Fund0.00%0.00%0.00%0.00%0.00%NITENightstar Therapeutics-0.04%+2.16%+5.01%+31.38%+21.77%WMWELEMENTS Linked to the Morningstar Wide Moat Focus Total Return Index0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAZTDAztlan Global Stock Selection DM SMID ETFN/AN/AN/AN/AN/AN/AN/AN/AFVLFirst Trust Value Line 100 Exchange-Traded FundN/AN/AN/AN/AN/AN/AN/AN/ANITENightstar TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AWMWELEMENTS Linked to the Morningstar Wide Moat Focus Total Return IndexN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAZTDAztlan Global Stock Selection DM SMID ETF 2.51Moderate Buy$26.95N/AFVLFirst Trust Value Line 100 Exchange-Traded Fund 0.00N/AN/AN/ANITENightstar Therapeutics 0.00N/AN/AN/AWMWELEMENTS Linked to the Morningstar Wide Moat Focus Total Return Index 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAZTDAztlan Global Stock Selection DM SMID ETFN/AN/AN/AN/AN/AN/AFVLFirst Trust Value Line 100 Exchange-Traded FundN/AN/AN/AN/AN/AN/ANITENightstar TherapeuticsN/AN/AN/AN/A$5.89 per shareN/AWMWELEMENTS Linked to the Morningstar Wide Moat Focus Total Return IndexN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAZTDAztlan Global Stock Selection DM SMID ETFN/AN/A12.62∞N/AN/AN/AN/AN/AFVLFirst Trust Value Line 100 Exchange-Traded FundN/AN/A0.00∞N/AN/AN/AN/AN/ANITENightstar Therapeutics-$36.86M-$1.26N/AN/AN/AN/A-30.89%-27.65%N/AWMWELEMENTS Linked to the Morningstar Wide Moat Focus Total Return IndexN/AN/A0.00N/AN/AN/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAZTDAztlan Global Stock Selection DM SMID ETF$0.421.56%N/AN/AN/AFVLFirst Trust Value Line 100 Exchange-Traded Fund$0.271.17%N/AN/AN/ANITENightstar TherapeuticsN/AN/AN/AN/AN/AWMWELEMENTS Linked to the Morningstar Wide Moat Focus Total Return IndexN/A0.00%N/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAZTDAztlan Global Stock Selection DM SMID ETFN/AN/AN/AFVLFirst Trust Value Line 100 Exchange-Traded FundN/AN/AN/ANITENightstar TherapeuticsN/A8.548.54WMWELEMENTS Linked to the Morningstar Wide Moat Focus Total Return IndexN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAZTDAztlan Global Stock Selection DM SMID ETFN/AFVLFirst Trust Value Line 100 Exchange-Traded FundN/ANITENightstar Therapeutics32.83%WMWELEMENTS Linked to the Morningstar Wide Moat Focus Total Return IndexN/AInsider OwnershipCompanyInsider OwnershipAZTDAztlan Global Stock Selection DM SMID ETFN/AFVLFirst Trust Value Line 100 Exchange-Traded FundN/ANITENightstar TherapeuticsN/AWMWELEMENTS Linked to the Morningstar Wide Moat Focus Total Return IndexN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAZTDAztlan Global Stock Selection DM SMID ETFN/A1.13 millionN/ANot OptionableFVLFirst Trust Value Line 100 Exchange-Traded FundN/A1.59 millionN/ANot OptionableNITENightstar Therapeutics4733.54 millionN/ANot OptionableWMWELEMENTS Linked to the Morningstar Wide Moat Focus Total Return IndexN/A544,000N/ANot OptionableWMW, AZTD, NITE, and FVL HeadlinesRecent News About These CompaniesMorningstar Wide Moat Focus (MWMF)December 20, 2023 | investing.comSP500-3030TR S&P 500 Household & Personal Products Index Industry Group - Total ReturnOctober 28, 2023 | seekingalpha.comMorningstar Wide Moat Focus Index Performance Analysis for AdvisorsAugust 18, 2023 | morningstar.comMMorningstar Wide Moat Focus 20 (^MWMFT)May 20, 2023 | finance.yahoo.comKSM 4D Morningstar Wide Moat Focus (KSMF118)March 22, 2023 | uk.investing.comSMID Moat Index Starts StrongJanuary 12, 2023 | seekingalpha.comELEMENTS Linked to the Morningstar Wide Moat Focus Total Return Index (WMW)November 28, 2022 | finance.yahoo.comMOAT: Still Not Appealing After Q3 ReconstitutionSeptember 21, 2022 | seekingalpha.comMedia Sentiment Over TimeTop HeadlinesView All HeadlinesDo They Know Something? Insiders & Congress Buy UnitedHealthBy Brian O'Connell | July 9, 2025View Do They Know Something? Insiders & Congress Buy UnitedHealthTop Steel Picks for the Coming Infrastructure BoomBy Chris Markoch | June 25, 2025View Top Steel Picks for the Coming Infrastructure BoomInsiders Spent Millions on These 3 Stocks Over the Past 2 MonthsBy Leo Miller | July 17, 2025View Insiders Spent Millions on These 3 Stocks Over the Past 2 MonthsUPS Is Outpacing the Market: A Green Light for Investors?By Jeffrey Neal Johnson | June 27, 2025View UPS Is Outpacing the Market: A Green Light for Investors?Reddit Stock Ignites: Surge in Call Options Signals Big BetBy Gabriel Osorio-Mazilli | June 24, 2025View Reddit Stock Ignites: Surge in Call Options Signals Big BetWMW, AZTD, NITE, and FVL Company DescriptionsAztlan Global Stock Selection DM SMID ETF NYSEARCA:AZTD$26.95 -0.08 (-0.30%) As of 04:10 PM EasternThe Aztlan Global Stock Selection Dm SMID ETF (AZTD) is an exchange-traded fund that mostly invests in extended market equity. The fund tracks an equal-weighted index of 27 mid- and small-cap stocks from developed markets, selected based on six factors: value, cashflow, capital structure, growth, EPS revisions, and price momentum. AZTD was launched on Aug 18, 2022 and is managed by Aztlan.First Trust Value Line 100 Exchange-Traded Fund NYSEARCA:FVL$23.16 -0.01 (-0.04%) As of 12/11/2020First Trust Value Line 100 Exchange-Traded Fund (the Fund) seeks investment results that correspond generally to the price and yield of an equity index called the Value Line 100 Index (the Index). The Index is an equal-dollar weighted index that is designed to objectively identify and select 100 stocks from the universe of stocks, to which Value Line assigns a #1 ranking in the Value Line Timeliness Ranking System (the Ranking System). At any one time, only 100 stocks are assigned a #1 ranking in the Ranking System. The Index is rebalanced quarterly. The Fund will normally invest at least 90% of its assets in common stocks that comprise the Index. The Fund's investment advisor is First Trust Advisors L.P.Nightstar Therapeutics NASDAQ:NITENightstar Therapeutics plc, a clinical-stage gene therapy company, focuses on developing and commercializing novel one-time treatments for patients suffering from rare inherited retinal diseases in the United Kingdom. The company's lead product candidate is NSR-REP1, a candidate that is in phase 3 clinical development for the treatment of patients with choroideremia. It is also developing NSR-RPGR, a candidate that is in Phase 1/2 clinical trials for the treatment of patients with X-linked retinitis pigmentosa, an inherited X-linked recessive retinal disease; and NSR-BEST1, a candidate that is in preclinical development stage for the treatment of best vitelliform macular dystrophy. In addition, the company is developing NSR-ABCA4, a candidate that is in preclinical development stage for the treatment of Stargardt disease. The company was founded in 2013 and is headquartered in London, the United Kingdom.ELEMENTS Linked to the Morningstar Wide Moat Focus Total Return Index NYSEARCA:WMW More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Netflix Q2 2025 Earnings: What Investors Need to Know High-Flying GE Aerospace Drops After Blowout Q2 — What Now? A New $70 Billion AI Investment Could Push Taiwan Semiconductor Why Prologis May Be the Smartest Backdoor Bet on AI Real Estate Snap-On: Snap Up This Strong Signal While It’s Still Cheap Why Abbott Laboratories Is a Q2 2025 Buy: Growth & Yield Why Pure Storage Is a Core Investment for the AI Era How Goldman Sachs Earnings Help You Strategize Your Portfolio Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.